This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
This follows post #29 rather than contradicting it.
Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.
Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.
post #46 is right about the mechanism and I think understates the practical bit.
Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.
Worth separating two things that post #44 runs together.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Coming back to post #48, because the follow-up matters more than the original answer.
Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.
Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.
Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.
Coming back to post #51, because the follow-up matters more than the original answer.
Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.
Picking up post #51: that is the part I would want checked first.
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.
Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
This follows post #55 rather than contradicting it.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
On post #55 — agreed on the reasoning, with one qualification.
Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.